ClinicalTrials.gov: NCT07567001 (HF-POLARIS) | Mechanism: GLP-1 / amylin dual agonist TRIAL SPOTLIGHT Educational spotlight selected by editors Semaglutide Without the Needle: A Dissolving Microarray Patch Enters the Clinic Terrestrial Bio (formerly Vaxess Technologies) dosed the first patients on July 1, 2026, in a Phase 1 trial (NCT07673900) evaluating VX-201, a needle-free microarray patch branded as Tacterra that delivers the established GLP-1 receptor agonist semaglutide
Clinical trials involving tirzepatide reveal a dose-dependent effect on HbA1c across all five trials, with mean baseline decreases ranging from 1.87% to 2.59%
Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat
The pituitary gland, situated at the base of the brain, plays a crucial role in regulating various hormones in the body, including growth hormones
They can help determine whether a semaglutide dosage or tirzepatide dosage (Ozempic, Wegovy, Zepbound and Mounjaro) adjustment is necessary, or if other factors are affecting your progress
That sounds
